Hip Osteoarthritis and Platelet-rich plasma (PRP): what the trial registry contains
The ClinicalTrials.gov registry holds 14 records for PRP in Hip Osteoarthritis: 7 recruiting now, 3 labelled Phase 3 or 4, across 6 countries. Snapshot 2026-08-29.
Why this is studied in Hip Osteoarthritis
Hip osteoarthritis involves cartilage loss in a deep, high-load joint with limited access for injection and less intra-articular volume than the knee. Registered cell work is markedly thinner here than for knees, which is a useful cross-check when a clinic quotes knee data to justify a hip procedure.
What PRP means in this table
Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.
The numbers
Every figure below comes from one reproducible query (hip osteoarthritis x platelet-rich plasma) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 14 |
| Interventional studies in the sample | 13 |
| Recruiting right now | 7 |
| Completed | 4 |
| Terminated, withdrawn or suspended | 1 |
| Phase 3 or Phase 4 records | 3 |
| Countries with at least one site | 6 |
| Median planned enrolment | 82 participants |
| Largest single planned enrolment | 10,000 participants |
| First / most recent start year | 2013 — 2025 |
How mature is this evidence?
Later-phase work exists but is not dominant (3 of 14), which is the typical profile of a field that has shown safety and is still testing whether benefit survives a control arm.
The delivery record matters as much as the count: 4 completed against 1 abandoned or suspended, or 7% of everything registered.
| Phase label | Records | Share |
|---|---|---|
| Not applicable | 9 | 64% |
| Phase 3 | 2 | 14% |
| Phase 2 | 1 | 7% |
| Phase 4 | 1 | 7% |
| Phase 1 | 1 | 7% |
Median planned enrolment is 82 participants (largest single study: 10,000). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Country coverage runs to 6, but the distribution has a long tail behind United States at about 57% of mentions.
| Country | Studies with a site there |
|---|---|
| United States | 8 |
| Turkey (Türkiye) | 2 |
| Spain | 1 |
| Canada | 1 |
| Italy | 1 |
| Finland | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
The sponsor mix is academic (5 academic or hospital, 2 commercial among the most frequent lead sponsors).
- Massachusetts General Hospital — 2 records
- University of Colorado, Denver — 1 record
- Fundación Pública Andaluza Progreso y Salud — 1 record
- VivaTech International, Inc. — 1 record
- University of Utah — 1 record
- Firat University — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT06793982 — Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain | Phase 4 | Recruiting | 54 | LifeBridge Health | 2024-02-21 |
| NCT06003101 — Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | Phase 3 | Recruiting | 160 | Massachusetts General Hospital | 2023-08-30 |
| NCT02844764 — Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip | Phase 2 | Recruiting | 4,000 | VivaTech International, Inc. | 2015-07 |
| NCT07231471 — Platelet Rich Plasma for Musculoskeletal Conditions | n/a | Recruiting | 10,000 | University of Utah | 2025-12-29 |
| NCT05497349 — Use of Leukocyte-Rich PRP or Leukocyte-Free PRP in the Treatment of Hip Osteoarthritis | n/a | Recruiting | 230 | Istituto Ortopedico Rizzoli | 2022-10-05 |
| NCT04238143 — Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis | n/a | Recruiting | 100 | Healeon Medical Inc | 2020-01-10 |
| NCT03909139 — Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear | n/a | Recruiting | 400 | Massachusetts General Hospital | 2019-09-06 |
| NCT02694146 — Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis | Phase 3 | Completed | 74 | Fundación Pública Andaluza Progreso y Salud | 2016-03 |
| NCT04241354 — A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis | Phase 1 | Unknown | 84 | Regenerative Orthopedics and Sports Medicine | 2021-08-25 |
| NCT07307118 — Functional Hip Strength Improvement in Knee Osteoarthritis Following Single-Dose PRP and a 6-Week Home Exercise Program | n/a | Completed | 27 | Firat University | 2025-07-08 |
What this page does and does not tell you
Registration counts measure activity, not effect. A study appears here the moment it is registered — before any participant is enrolled, and regardless of whether results are ever posted.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many PRP studies for Hip Osteoarthritis are recruiting right now?
7 of 14 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is PRP an approved treatment for Hip Osteoarthritis?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 14 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on PRP for Hip Osteoarthritis?
3 of 14 records carry a Phase 3 or Phase 4 label and 4 are marked completed. Registrations run from 2013 to 2025.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.